Emulate Energy and Smartcar Partner to Drive EV Utilization as Distributed Energy Resources
14.11.2024 08:00:00 CET | Business Wire | Press Release
Emulate Energy, distributed energy resource management system (DERMS) software, today announced a partnership with Smartcar, the leading API platform for mobility businesses. By seamlessly integrating EVs into its platform, Emulate offers energy providers a comprehensive solution to simplify onboarding and management of different consumer distributed energy resources (DERs).
This partnership enables energy providers using Emulate to use EV charging flexibility effectively as a way to balance the grid, reduce peak demand, and improve overall grid reliability.
Enabling reliable EV integration for energy providers
By expanding its EV support to a wider range of models, Emulate is enabling energy providers to harness the power of EVs as a valuable energy resource. Smartcar helps Emulate automate EV data retrieval to optimize charging schedules based on different pricing factors. Consumers can set their preferred charging preferences using the software and have peace of mind knowing Emulate will handle the rest.
Reliable EV integrations are crucial for enabling this convenience and giving consumers a single platform to enroll and manage different devices.
“Emulate aspires to connect to and control every energy device possible. While controls and market participation are our bread-and-butter, for EVs specifically, Smartcar makes it super easy to connect to vehicles regardless of manufacturer and model,” says Blake Davis, Senior Director of US Operations at Emulate.
A strategic partnership for scalability
Emulate’s decision to partner with Smartcar was driven by the need for a reliable and scalable solution that they could implement quickly without straining engineering resources. Smartcar ensures accurate and timely action, like retrieving an EV’s state of charge and automatically starting and stopping charging sessions. Smartcar is compatible with over 35 EV brands and seamlessly integrates into Emulate’s out-of-the-box vehicle onboarding solution.
Beyond endpoints, Smartcar’s developer tools and webhooks make it easy for Emulate’s engineering team to receive data at a regular cadence while reducing server loads, reducing latency, and ensuring the timeliness and accuracy of charging data.
A shared vision for the future of distributed energy
“Emulate’s commitment to energy flexibility and reliability aligns perfectly with Smartcar’s mission. By simplifying EV integrations and enabling proactive load control, we’re excited to help Emulate empower drivers to reduce their energy costs, support grid stability, and contribute to a more sustainable future,” says Sahas Katta, CEO and Co-founder at Smartcar.
This partnership will help address the challenges associated with EV enrollment and retention in demand response programs. Emulate and Smartcar aim to increase EV participation and drive long-term adoption by simplifying EV onboarding processes, improving feature reliability, and providing a user-friendly experience for all consumers.
About Emulate
Emulate Energy is a rapidly growing software company from Sweden, the forefront of the energy transition. Founded in 2020 based on research conducted at MIT, the company aims to expedite the global shift to sustainable power. Emulate’s cutting-edge software optimizes the energy consumption of common devices—air conditioners, heat pumps, and EV chargers— to save consumers money while enhancing utility profits by aggregating these devices into “virtual batteries” that can be dispatched or traded on electricity markets. Tailored for utilities by utilities, our solutions have impacted thousands of customers across Europe and the US, contributing to a greener, more robust energy future.
About Smartcar
Smartcar, the leading API platform for connected vehicles, empowers businesses to develop mobility solutions that put drivers in control of their vehicle data. Founded in 2015, Smartcar provides developer tools to help companies integrate with cars using a unified API, manage API connections, and implement consent management. Smartcar unlocks the freedom of movement for everyone by removing barriers to mobility app development and helping vehicle owners choose how they want to use their car data — whether that’s on solutions for energy management, vehicle repairs, EV charging, rideshare, auto insurance, and more. Smartcar has raised $36M to date and is backed by Andreessen Horowitz (a16z), New Enterprise Associates (NEA), and Energize Capital.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113990311/en/
Contacts
Winona Rajamohan
Smartcar
winona@smartcar.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press Release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom